GHK-Cu Clinical Trials: Registered Studies and Status
As of November 2, 2026, ClinicalTrials.gov lists 2 registered studies matching GHK-Cu or its known aliases as an intervention.
Summary
- Registered studies
- 2
- Most advanced phase
- Phase 2
- Recruiting or not yet recruiting
- 2
- Most recent start
- 2027-01
- Most frequent lead sponsor
- Hudson Biotech (1)
- Most common status
- Not yet recruiting
Source: ClinicalTrials.gov, retrieved . Registry searches by name may miss studies that use other identifiers.
Registered studies
| NCT ID | Title | Phase | Status | Enrollment | Start | Lead sponsor |
|---|---|---|---|---|---|---|
| NCT07706361 | Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults | Not applicable | Not yet recruiting | 100 | 2027-01 | LifeWave, Inc. |
| NCT07437586 | Topical GHK-Cu Gel for Acute Skin Wound Healing | Phase 2 | Recruiting | 60 | 2026-02-02 | Hudson Biotech |
Method and limitations
- Data source: ClinicalTrials.gov API v2, intervention search.
- Query used:
"GHK-Cu" OR "copper tripeptide-1" OR "GHK copper" - Retrieved: November 2, 2026. Refreshed weekly; changes are reviewed before publication.
- Studies registered only under other names, sponsor codes, or in other registries may be missing.
- A match on name does not mean the study tested this peptide alone; some studies include it as a comparator or combination.
- Status values are reported by sponsors and may be out of date.